Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Graves opthalmopathy and psychoendocrinopathies.

Ghanem AA, Amr MA, Araafa LF.

Middle East Afr J Ophthalmol. 2010 Apr;17(2):169-74. doi: 10.4103/0974-9233.63079.

2.

Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.

De Bellis A, Bizzarro A, Conte M, Coronella C, Solimeno S, Perrino S, Sansone D, Guaglione M, Wall JR, Bellastella A.

Clin Endocrinol (Oxf). 2003 Sep;59(3):388-95.

PMID:
12919164
3.

TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients.

Mukasa K, Yoshimura Noh J, Kouzaki A, Ohye H, Kunii Y, Watanabe N, Yoshihara A, Matsumoto M, Suzuki M, Ito K.

Endocr J. 2016;63(2):151-7. doi: 10.1507/endocrj.EJ15-0137. Epub 2015 Nov 18.

5.

Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.

Woo YJ, Jang SY, Lim TH, Yoon JS.

Korean J Ophthalmol. 2015 Aug;29(4):213-9. doi: 10.3341/kjo.2015.29.4.213. Epub 2015 Jul 21.

6.
8.

Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.

Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J, Morgenthaler NG.

Clin Endocrinol (Oxf). 2004 Nov;61(5):612-8.

PMID:
15521965
9.

Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.

Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF.

Clin Endocrinol (Oxf). 2000 Mar;52(3):267-71.

PMID:
10718823
10.

New immunomodulators in the treatment of Graves' ophthalmopathy.

Salvi M, Vannucchi G, Campi I, CurrĂ² N, Beck-Peccoz P.

Ann Endocrinol (Paris). 2008 Apr;69(2):153-6. doi: 10.1016/j.ando.2008.02.013. Epub 2008 Apr 15.

PMID:
18417090
11.

Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.

Salvi M, Vannucchi G, Campi I, CurrĂ² N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P.

Eur J Endocrinol. 2007 Jan;156(1):33-40.

12.

Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.

Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE; Basedow Study Group..

Thyroid. 2005 Sep;15(9):1047-54.

PMID:
16187913
13.

[Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].

Komaki T, Sakata S, Nakamura S, Matsuda M, Kojima N, Takuno H, Miura K.

Nihon Naibunpi Gakkai Zasshi. 1989 Jul 20;65(7):627-39. Japanese.

PMID:
2583311
14.

Serum immunoglobulin G4 levels and Graves' disease phenotype.

Martin CS, Sirbu AE, Betivoiu MA, Florea S, Barbu CG, Fica SV.

Endocrine. 2017 Feb;55(2):478-484. doi: 10.1007/s12020-016-1157-5. Epub 2016 Nov 7.

PMID:
27819113
15.

Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.

Aizawa T, Ishihara M, Koizumi Y, Hashizume K, Takasu N, Yamada T, Kobayashi I, Watanabe T, Shimizu Z.

Am J Med. 1990 Aug;89(2):175-80.

PMID:
2166430
16.

Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: their incidence, significance and clinical usefulness.

Macchia E, Concetti R, Borgoni F, Cetani F, Fenzi GF, Pinchera A.

Autoimmunity. 1989;3(2):103-12.

PMID:
2577491
17.

A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.

Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ.

J Clin Endocrinol Metab. 2010 May;95(5):2123-31. doi: 10.1210/jc.2009-2470. Epub 2010 Mar 17.

PMID:
20237164
18.

Psychiatric symptoms and diagnoses in thyroid disorders: a cross-sectional study.

Aslan S, Ersoy R, Kuruoglu AC, Karakoc A, Cakir N.

Int J Psychiatry Clin Pract. 2005;9(3):187-92. doi: 10.1080/13651500510029129.

PMID:
24937789
19.

Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.

De Bellis A, Conzo G, Cennamo G, Pane E, Bellastella G, Colella C, Iacovo AD, Paglionico VA, Sinisi AA, Wall JR, Bizzarro A, Bellastella A.

Endocrine. 2012 Apr;41(2):320-6. doi: 10.1007/s12020-011-9559-x. Epub 2011 Nov 16.

PMID:
22169963
20.

Thyrotropin receptor antibodies in hypothyroid Graves' disease.

Kasagi K, Hidaka A, Nakamura H, Takeuchi R, Misaki T, Iida Y, Konishi J.

J Clin Endocrinol Metab. 1993 Feb;76(2):504-8.

PMID:
8094394

Supplemental Content

Support Center